TP53 and acute myeloid leukemia: In another analysis comparing patients with MDS-EB2 with complex karyotype and TP53 mutation to patients with AML and similar genetic characteristics, the two groups were largely indistinguishable and had uniformly poor outcomes regardless of blast count (58).